Embecta Corp. EMBC
Medical/Dental Instruments · data as of November 13, 2026
Embecta Corp. (EMBC) is a healthcare company listed in the US with a market value of about $366M. In the twelve months to June 30, 2026 it had revenue of $1.0B and net income of $88M, a net margin of 8.6%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is value (4/5); the weakest is future growth (1/5).
Key numbers: a P/E of 4.4, a price to free cash flow of 2.2, 5-year revenue growth of -0% a year, a 5-year average ROIC of 32%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 468% above the current price.
About Embecta
Embecta is listed in the US and classified in medical/dental instruments. Revenue went from $1.1B in 2020 to $1.1B in 2025, a decline of about 0.1% a year. It was profitable in 6 of the last 6 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 3% of revenue on research and development.
Score: 2.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Positive free cash flow
Checks not passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- ROE above 15%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.1B | $1.1B | $1.1B | $1.1B | $1.2B | $1.1B |
| Net income | $88M | $95M | $78M | $70M | $224M | $415M | $428M |
| Free cash flow | $165M | $182M | $20M | $41M | $389M | $420M | $457M |
| EPS (diluted) | $1.47 | $1.62 | $1.34 | $1.22 | $3.89 | $7.28 | $7.50 |
| Net margin | 8.6% | 8.8% | 7.0% | 6.3% | 19.8% | 35.6% | 39.4% |
| ROIC | — | 22.2% | 15.4% | 17.7% | 35.5% | 68.9% | 74.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $4.00, 38% below the current price; targets range from $3.00 to $5.00; the consensus rating is “none”; expected EPS is $1.83 for the fiscal year ending September 30, 2026.
Frequently asked questions
What is Embecta’s P/E ratio?
About 4.4, based on the last twelve months of diluted earnings per share (forward P/E about 3.9).
Is Embecta stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 468% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Embecta pay a dividend?
Yes. The dividend yield is about 0.62%, and it has paid dividends for 4 years in our data.
Is Embecta a good stock to buy?
We do not give buy or sell advice. Embecta scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.